Based in the Netherlands, Fysicon Medical Technology is a leader in the field of cardiology. The company will distribute the T-Stat® VLS Tissue Oximeter and Sensors to the Dutch, Belgium, and Luxembourgian (Benelux), and Suriname markets.
Based in Italy, A.M.I. Italia s.r.l. is a leader in the patient monitoring market. A.M.I. will distribute the T-Stat® VLS Tissue Oximeter and Sensors in Italy, France, Spain, Portugal, Poland, Greece, Turkey, and Russia.
Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead product, the T-Stat Tissue Oximeter, was the first medical device FDA approved as sensitive to ischemia, an insufficient blood flow to tissue. T-Stat is the only commercially available tissue oximeter that utilizes state-of-the-art visible light spectroscopy (VLS) technology. In clinical use, T-Stat is a real-time, absolute, non-invasive, and continuous tissue monitor that analyzes 260 wavelengths of light, far more than the 2-4 wavelengths used in other monitors for superior accuracy. Spectros is also developing molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally. For further information, contact Elizabeth van Thillo, Marketing, Spectros Corporation, at email@example.com or 650/529.2865
Copyright©2009 PR Newswire.
All rights reserved